Bisoprolol attenuates noradrenaline- and phenylephrine-evoked venoconstriction in man in vivo

被引:3
作者
Abdelmawla, AH [1 ]
Langley, RW [1 ]
Szabadi, E [1 ]
Bradshaw, CM [1 ]
机构
[1] QUEENS MED CTR,DEPT PSYCHIAT,NOTTINGHAM NG7 2UH,ENGLAND
关键词
bisoprolol; noradrenaline; phenylephrine; dorsal hand vein; beta(1)-adrenoceptor antagonist;
D O I
10.1046/j.1365-2125.1997.00624.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims The aim of this study was to examine the effects of bisoprolol (BIS), a selective beta 1-adrenoceptor antagonist without partial agonistic activity, on noradrenaline- and phenylephrine-evoked venoconstriction in man using the dorsal hand vein compliance technique. Methods Twelve healthy male volunteers participated in three weekly experimental sessions. Subjects were allocated to treatments and sessions on a double-blind basis. In each session either BIS 5 mg (BIS5), or BIS 10 mg (BIS10), or placebo was administered orally, and nonadrenaline acid tartrate (0.1-33.33 ng min(-1)) followed by phenylephrine hydrochloride (0.033-10 mu g min(-1)) was infused into the dorsal hand vein. Systolic and diastolic blood pressure and heart rate were also measured. Results Both noradrenaline and phenylephrine produced dose-dependent venoconstriction: the geometric mean ED50 for noradrenaline was 3.21 ng min(-1) and for phenylephrine 135.04 ng min(-1); the potency ratio (noradrenaline/phenylephrine) was 42. Both BIS5 and BIS10 significantly decreased the venoconstriction to noradrenaline (ANOVA; P < 0.005), and to phenylephrine (ANOVA; P < 0.001). The antagonism of the venoconstrictor responses was also reflected in a significant increase in logED(50) values for both noradrenaline (ANOVA; P < 0.005), and phenylephrine (ANOVA; P < 0.0025) in the presence of both doses of BIS. Both doses of BIS significantly decreased heart rate (ANOVA; P < 0.0001), and systolic blood pressure (ANOVA; P < 0.0025). Conclusions Bisoprolol can antagonize alpha(1)-adrenoceptor mediated venoconstriction in the human dorsal hand vein in vive through a mechanism which remains to be elucidated.
引用
收藏
页码:61 / 67
页数:7
相关论文
共 40 条
[1]  
ABDELMAWLA AH, 1995, BRIT J CLIN PHARMACO, V40, P445
[2]  
ABDELMAWLA AH, 1996, BR J CLIN PHARM, V41
[3]   A NEW TECHNIQUE FOR RECORDING COMPLIANCE OF HUMAN HAND VEINS [J].
AELLIG, WH .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1981, 11 (03) :237-243
[4]   LONGITUDINAL-STUDY OF MECHANISMS OF ACTION OF DEBRISOQUINE AND PROPRANOLOL [J].
AMINU, J ;
VERE, DW .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1978, 6 (01) :43-50
[5]  
AMINU JM, 1972, CLIN SCI, V42, pP3
[6]  
ARIENS EJ, 1964, MOL PHARMACOL, P287
[7]  
BEERMANN C, 1992, CLIN INVESTIGATOR, V70, pS13
[8]   CONSTRICTION OF HUMAN DORSAL HAND VEINS INVIVO WITH SEVERAL VASOCONSTRICTORS AND THE INFLUENCE OF ORAL-ADMINISTRATION OF CARVEDILOL [J].
BEERMANN, C ;
SCHLOOS, J ;
BELZ, GG .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1992, 19 :S12-S17
[9]  
BELZ GG, 1988, DRUGS S6, V36, P69
[10]  
BLOCHLDAUM B, 1991, N-S ARCH PHARMACOL, V344, P302